Builds on momentum following appointment of CEO and completion of Phase III clinical trials for PlasmaCap IG (Intravenous Immunoglobulin or “IVIG”) MISSISSAUGA, Ontario--(BUSINESS WIRE)--Evolve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback